ANA
LLUCH HERNANDEZ
EMÉRITO/A UNIVERSIDAD
Instituto de Investigación Sanitaria Fundación para la Investigación del Hospital Clínico de Valencia
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria Fundación para la Investigación del Hospital Clínico de Valencia (14)
2022
-
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
Science Advances, Vol. 8, Núm. 20
2021
2020
-
Circulating mir-99a-5p expression in plasma: A potential biomarker for early diagnosis of breast cancer
International Journal of Molecular Sciences, Vol. 21, Núm. 19, pp. 1-14
2019
-
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
Frontiers in Oncology, Vol. 9, Núm. APR
-
A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients
Clinical Epigenetics, Vol. 11, Núm. 1
-
Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion
European Journal of Cancer, Vol. 120, pp. 54-64
-
The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors
Scientific Reports, Vol. 9, Núm. 1
2017
-
Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer
Clinical Cancer Research, Vol. 23, Núm. 22, pp. 7006-7019
2015
-
MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer
Journal of Cellular Biochemistry, Vol. 116, Núm. 9, pp. 2061-2073
2014
-
Oxidative stress in susceptibility to breast cancer: Study in Spanish population
BMC Cancer, Vol. 14, Núm. 1
-
Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer
Clinical and Translational Oncology, Vol. 16, Núm. 9, pp. 814-822
2010
-
¿Qué avances nos ofrece la moderna Oncología?
Anales (Reial Acadèmia de Medicina de la Comunitat Valenciana), Núm. 11
2005
-
Development of a questionnaire to measure health-related quality of life (HRQoL) in patients with bone metastases (BOMET-QoL)
Journal of Outcomes Research, Vol. 9, Núm. 15-27, pp. 15-27